Nascent Sarcopenia Pipeline’s First Target Is Myostatin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biologics affecting myostatin signaling are at the forefront of the R&D pipeline for sarcopenia, with leading candidates in Phase II from Sanofi/Regeneron, Lilly and Novartis.